Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

导出 OA

翻译打印收藏纠错

第一作者： Muntasir Mamun,Majumder

第一单位： Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.

作者： Muntasir Mamun,Majumder ^[1] ; Raija,Silvennoinen ^[2] ; Pekka,Anttila ^[3] ; David,Tamborero ^[4] ; Samuli,Eldfors ^[1] ; Bhagwan,Yadav ^[1] ; Riikka,Karjalainen ^[1] ; Heikki,Kuusanmäki ^[1] ; Juha,Lievonen ^[3] ; Alun,Parsons ^[1] ; Minna,Suvela ^[1] ; Esa,Jantunen ^[5] ; Kimmo,Porkka ^[6] ; Caroline A,Heckman ^[1]

作者单位： Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. ^[1] Department of Medicine, Kuopio University Hospital, Kuopio, Finland.;Department of Hematology, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland. ^[2] Department of Hematology, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland. ^[3] Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, University Pompeu Fabra, Barcelona, Spain. ^[4] Department of Medicine, Kuopio University Hospital, Kuopio, Finland. ^[5] Department of Hematology, Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland.;Hematology Research Unit, University of Helsinki, Helsinki, Finland. ^[6]

关键词 drug sensitivity and resistance testing functional screening high-risk myeloma multiple myeloma precision medicine

DOI 10.18632/oncotarget.17630

PMID 28915594

发布时间 2018-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交